Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "ERSPC European Randomized Study Screening Prostate Cancer" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about ERSPC European Randomized Study Screening Prostate Cancer for you to read. Along with our medical data and news we also list ERSPC European Randomized Study Screening Prostate Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of ERSPC European Randomized Study Screening Prostate Cancer Companies for you to search.
A BMJ Rapid Recommendation in this issue1 reviews the evidence2 behind prostate cancer screening, including the latest large trial of prostate cancer screening with the prostate-specific antigen...
What you need to knowPSA testing has increased the number of men diagnosed with and treated for prostate cancer, but many of these men would never have experienced any symptoms or death from prostate...
This article addresses prostate cancer screening and the research around its potential benefits and harms.
Dr Charles Vega comments on two studies, each looking at a different issue related to prostate cancer screening. Medscape Internal Medicine
Dr Gerald Chodak discusses recent findings from a retrospective analysis on the magnitude of benefit with prostate cancer screening. Medscape Urology
(Reuters Health) - Most men shouldn't get routine prostate cancer screening because the potential benefits are small and there are clear harms, an international panel of experts concludes.
Are patients being diagnosed with more advanced prostate cancer now that PSA screening recommendations have changed? Dr Chodak reviews a study seeking to answer this question. Medscape Urology
Alex H. Krist, MD, MPHDavid F. Penson, MD, MPH
A panel of experts from the United Kingdom is asking whether regular screening for prostate cancer actually brings enough benefits to outweigh the risks.
WEDNESDAY, Dec. 12, 2018 -- For certain men with early prostate cancer, choosing surgery over "watchful waiting" may add a few years to their lives, a new study suggests. European researchers found that among nearly 700 men with earlier-stage...
The USPSTF's recently updated prostate cancer screening guidelines will challenge physicians to deliver accurate information to patients quickly and easily, argues Dr Gerald Chodak. Medscape Urology
Review in-depth clinical information, latest medical news, and guidelines on prostate cancer and prostate cancer treatment including prostate cancer surgery. Learn about prostate cancer prognosis for advanced prostate cancer.
THURSDAY, Sept. 6, 2018 -- Prostate cancer screening with prostate-specific antigen (PSA) testing is not recommended, although certain groups of men are more likely to undergo testing, according to a review and recommendations published online Sept....
Screening for prostate cancer may result in a small absolute benefit in disease-specific mortality over 10 years but does not improve overall mortality. Medscape Medical News
THURSDAY, Oct. 11, 2018 -- Midlife levels of prostate-specific antigen (PSA) strongly predict future development of aggressive prostate cancer among black men, according to a study published online Sept. 17 in European Urology. Mark A. Preston,...
(Northwestern University) A double-blind, randomized phase III trial shows a drug currently used to treat men with metastatic, advanced prostate cancer significantly lowered the risk of metastasis or death when used in men with non-metastatic castrate-resistant prostate cancer and a rising PSA level.
Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term
HASBROUCK HEIGHTS, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce today important new long-term clinical trial results from the Company's 146 patient Phase IIb NX03-0040 Fexapotide (FT) U.S. study for low grade localized prostate cancer. All patients in the 78 month study had greater than or equal to 56 months from the time of enro...
MONDAY, July 23, 2018 -- Black men in the United States have higher rates of aggressive prostate cancer than other males. Now, a $26.5 million study is underway to figure out why. The U.S. National Institutes of Health and the Prostate Cancer...
(H. Lee Moffitt Cancer Center & Research Institute) In a new study published in European Urology, Moffitt Cancer Center researchers, along with colleagues at Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital in Boston, demonstrated that a baseline prostate-specific antigen (PSA) level obtained from black men between ages 40 and 60 can strongly predict future development of...
September marks National Prostate Health Month, when hospitals and urology practices push free prostate cancer screening. It’s also when we at HealthNewsReview.org publish our annual analysis of why these promotions — and their “screening saves lives” message — are bad for men. To help readers understand the issue more clearly, we’ve published an expande...
(Cedars-Sinai Medical Center) A new study has identified a novel molecular driver of lethal prostate cancer, along with a molecule that could be used to attack it. The findings were made in laboratory mice. If confirmed in humans, they could lead to more effective ways to control certain aggressive types of prostate cancer, the second-leading cause of cancer death for men in the US.
Source: Centers for Disease Control and PreventionRelated MedlinePlus Pages: Prostate Cancer Screening
(UNC Lineberger Comprehensive Cancer Center) Researchers examined the costs associated with screening for prostate cancer, including treatment, for three years after diagnosis. They estimated that for men diagnosed in each of 2004, 2005, 2006, and 2007, the total cost for treating and screening for each group would be $1.2 billion for three years after diagnosis.
Medical XpressProstate cancer care for older men estimated to cost Medicare $1.2 billionMedical XpressResearchers from the University of North Carolina Lineberger Comprehensive Cancer Center estimate that screening for and treating prostate cancer in men aged 70 years or older, which is not recommended by national guidelines, cost Medicare more than ...How Do You Spot Prostate Cancer Early On?Tech...